eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2021
vol. 38
 
Share:
Send email
Share:
abstract:
Original paper

A comparative analysis of tuberculosis in vitro screening in pemphigus patients selected for treatment with rituximab

Magdalena Jałowska
1, 2
,
Justyna Gornowicz-Porowska
1, 3
,
Agnieszka Seraszek-Jaros
4
,
Elżbieta Kaczmarek
4
,
Monika Bowszyc-Dmochowska
5
,
Paweł Bartkiewicz
1
,
Marian Dmochowski
1

  1. Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
  2. Occupational Medicine Outpatient Clinic, Œwiêcicki Hospital, Poznan University of Medical Sciences, Poznan, Poland
  3. Department and Division of Practical Cosmetology and Skin Diseases Prophylaxis, Poznan University of Medicinal Sciences, Poznan, Poland
  4. Department of Bioinformatics and Computational Biology, Poznan University of Medical Sciences, Poznan, Poland
  5. Cutaneous Histopathology and Immunopathology Section, Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
Adv Dermatol Allergol 2021; XXXVIII (4): 611–614
DOI: https://doi.org/10.5114/ada.2021.108904
Online publish date: 2021/09/14
View full text Get citation
 
Introduction
Patients qualified for the Polish government programme of treating severe pemphigus diseases with rituximab (RTX) available in 2018-2019 had to meet numerous criteria, including no active infectious disease. Aim: The clinical usefulness of tuberculosis screening with the QuantiFERON-TB Gold Plus (QFT-Plus) in native pemphigus patients selected for RTX treatment was statistically evaluated.

Material and methods
Eighteen pemphigus patients were examined with QFT-Plus prior to the intended RTX therapy. Ninety hospital employees examined with QFT-Plus due to contact with a cleaning worker who was diagnosed with active pulmonary tuberculosis were the control group.

Results
Six of 18 pemphigus patients had a positive QFT-Plus test result, one indefinite result and one initially indefinite and then negative. In the control group, 26 of 90 employees had a positive test result and none had an indefinite result. Statistical analysis by Fisher’s exact test showed no statistically significant difference in QFT-Plus positive results between the groups (p = 0.5577). Only in 1 patient with recurrent mucocutaneous pemphigus vulgaris previously treated with traditional immunosuppression, lung changes were detected by computed tomography. No employee had any changes in the chest radiograph.

Conclusions
Prior immunosuppression and autoimmunity might be the cause of indefinite test results, but they do not seem to increase positive results. In the native population, the QFT-Plus screening reveals a significant population exposure to M. tuberculosis infection independent of pemphigus autoimmunity, and such screening can be a starting point for identifying patients requiring anti-tuberculosis drug prophylaxis before combined RTX-glucocorticosteroid treatment.

keywords:

pemphigus, tuberculosis screening, rituximab
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.